drugset / Trial / NCT00066196
Evaluating The Antitumor Activity Of MEDI-522 With Or Without Dacarbazine In Patients With Metastatic Melanoma
RandomizedParallel-groupOpen-labelTreatment
Summary
The primary objectives of this study are: * To explore the antitumor activity of MEDI-522 ± DTIC in patients with metastatic melanoma. * To determine the safety of MEDI-522 ± DTIC in this patient population.
Timeline
- Start
- 2003-08
- Primary completion
- 2007-04
- Completion
- 2007-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dacarbazine | Small molecule | — | — |
| Comparator | etaracizumab | Monoclonal antibody | 100 mg | Intravenous |